Saccharomyces boulardii is a nonpathogenic yeast with proven health benefits, some of them depending on its viability. However, the living yeast is sensitive to environmental conditions and its viability is less than 1% in the faeces after oral administration. Therefore, we assessed the survival conditions of S. boulardii in aqueous suspension and in its freeze-dried form and we formulated microspheres with the former and tablets with the latter in order to preserve the viability of the probiotic. While the viability of the yeast in aqueous suspension could be maintained for one year at ؊20°C and ؉5°C, increasing the temperature led to almost total mortality within 14 d at ؉40°C and 4 d at ؉60°C. The viability of the freeze-dried yeast was preserved for one year at ؉25°C without moisture. With 75% relative humidity, the mortality was significant at 28 d at ؉25°C and almost total within 1 d at ؉60°C. In vitro, whereas less than 1% of non-encapsulated or non-tabletted S. boulardii survived after 120 min at pH 1.1, both formulations in microspheres and direct compression enabled to protect the yeast from degradation in HCl and to release it viable at pH 6.8. However, despite a similar release profile from both dosage forms, the compression led to a significant decrease in the viability of the freeze-dried yeast. In conclusion, although both formulations are efficient in protecting S. boulardii in acidic condition, microspheres provide a higher entrapment efficiency and a faster release of the viable probiotic in intestinal condition than matrix tablets.
Saccharomyces boulardii is a nonpathogenic yeast, clinically effective for the prevention and treatment of infectious enteritis and Clostridium-difficile-associated enterocolopathies. [1] [2] [3] [4] [5] [6] [7] Besides its use as an anti-diarrhoeal agent, 8) S. boulardii also exhibits beneficial effects on other intestinal pathologies like Crohn's disease 9) and ulcerative colitis. 10) As a living microorganism interacting with the intestinal microflora, S. boulardii is considered as a probiotic according to the definition of the World Health Organization, i.e. "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host". 11) Probiotics that are given orally have to firstly survive during the transit, and then persist in the gut to provide beneficial effects for the host. Concerning S. boulardii, some of its beneficial effects are dependent on the viable yeast concentration in the colon. 12) However, the survival of S. boulardii is challenged after oral administration and less than one per cent of the live yeast administered orally is recovered in faeces. 13) This weak ratio results from the destruction of the yeast during its transit within the gastro-intestinal tract especially regarding pH variations. 14) Increasing the percentage of living yeast within the intestine would therefore potentiate the therapeutical benefit of S. boulardii administration.
The aim of our study was therefore to formulate dosage forms able to protect the probiotic from degradation in acidic condition. We used two forms of S. boulardii as raw materials: the freeze-dried yeast (currently commercialised in hard capsules) and the aqueous suspension from which it was obtained. Preliminary assessment of the survival conditions of both forms of S. boulardii allowed selecting dosage forms and fabrication processes adapted to each form of probiotic, i.e. tablets and microspheres for the freeze-dried yeast and S. boulardii in aqueous suspension, respectively. Formulations were subsequently tested in simulated gastrointestinal conditions in vitro.
MATERIALS AND METHODS
Materials S. boulardii was supplied by Biocodex (Gentilly, France). It was presented under two forms: an aqueous suspension (viabilityϭ6.4Ϯ2.9ϫ10 10 colony forming unit (cfu)/g in batch 1; 7.8Ϯ0.7ϫ10 10 cfu/g in batch 2; 6.5Ϯ0.9ϫ 10 10 cfu/g in batch 3) and a freeze-dried powder (viabilityϭ5.2Ϯ2.2ϫ10 10 cfu/g in batch 4; 2.3Ϯ0.3ϫ10 10 cfu/g in batch 5; 2.6Ϯ0.2ϫ10 10 cfu/g in batch 6) obtained from the former. The suspension contained 75% of water and 25% of S. boulardii fresh extract and lactose (4 g/l of suspension) used as a cryoprotectant during the freeze-drying process. NaCl, Na 2 Assessment of the Survival of S. boulardii under Different Handling/Storage Conditions Samples of freeze-dried yeast (batch 4) were stored at ϩ25 or ϩ60°C either under aerobic conditions with 75% humidity or with no relative humidity, respectively (using saturated NaCl solution to maintain a constant humidity within the enclosure, or silicate gel to maintain the enclosure without humidity) or anaerobic conditions (nitrogen) for one year. A control sample was stored in ambient conditions for one year (temperature between ϩ15 and ϩ35°C and relative humidity from 35 to 90%). At 0, 1, 4, 7, 14, 28, 90, 180 d and one year, the freezedried yeast was sampled to evaluate its viability.
Samples of the aqueous suspension (batch 1) were stored at Ϫ20, ϩ5, ϩ25, ϩ40 and ϩ60°C under aerobic or anaerobic conditions for one year. At the times cited above, the aqueous suspension was sampled to assess the yeast viability. All the experiments were carried out in triplicate.
Determination of Viable Yeasts The viability of the yeast has been defined as the proportion of the cells that are capable of multiplication after incubation in standard microbiological conditions. It was evaluated after serial 10-fold dilutions by a plate culture method using Sabouraud and chloramphenicol agar at ϩ30Ϯ1°C for 72 h. Then, colonies on plates were enumerated and expressed as cfu/g of dry yeast extract. Detection limit was 10 2 cfu/g. Electron Microscopy For electron microscopic analysis, the following samples were examined using standard techniques: the freeze-dried yeast stored for 24 h at ϩ60°C with 75% relative humidity and the aqueous suspension of the yeast stored for 24 h at ϩ60°C. Control samples of each form of S. boulardii (freeze-dried and aqueous suspension), not submitted to any stress condition, were also examined. Briefly, each sample was fixed with 2.5% glutaraldehyde in 0.01 M PBS buffer (pH 7.4) overnight at ϩ4°C. Post fixation was carried out using a 2% osmium tetroxyde solution for 2 h at room temperature, and followed by dehydration through graded ethanol series. For scanning electron microscopy, samples were gold covered (1-2 nm) by cathodic spraying (Fine coat ion sputter JFC-1100, Jeol S.A., Tokyo, Japan) and examined at 17 kV using Jeol electron microscope (JSM-35CF, Jeol S.A.). For transmission electron microscopy study, each sample was embedded in Epon epoxy resin. Ultrathin sections (80-100 nm) were performed, stained with uranyl acetate and lead citrate and examined at 80 kV using Jeol electron microscope (JEM-100S, Jeol S.A.). At least 300 cells were examined in each sample and their general aspect (dense or light), the presence of vacuoles, the aspect of bud scars and existence of membrane alterations (deformation or rupture) were enumerated and expressed as percentages.
Formulation of Tablets. Preparation Matrix tablets (600 mg) containing 33.35% of freeze-dried S. boulardii (batch 5), 50.80% of Flowlac ® 100, 13.35% of Methocel ® K4M, 2% of talc and 0.5% of magnesium stearate were prepared by direct compression using an automatic single punch tablet press (Korsch EK0, Berlin, Germany) and 12 mm flatfaced punches. Two batches with hardness of 35Ϯ2 N and 79Ϯ6 N were prepared. Characterisation Uniformity of mass, resistance to crushing, friability and tablet disintegration were tested in accordance with the European Pharmacopoeia (5th edition).
In order to evaluate the influence of compression force on S. boulardii viability, tablets were crushed at room temperature and a mass of powder corresponding to 0.565 g of freeze-dried yeast was suspended in 20 ml of pH 6.8 phosphate buffer solution under magnetic stirring for 10 min. The viable yeasts were enumerated using the plate culture method described above. Experiments were carried out in triplicate. Results were expressed in log cfu/g of yeast.
In order to evaluate the release of viable yeast from tablets, the latter were placed successively in 1000 ml of 0.1 N HCl and pH 6.8 phosphate buffer at ϩ37°C for 2 h using a dissolution test apparatus (Prolabo, Fontenay sous Bois, France). Samples were collected at 5, 15, 30, 60 and 120 min in each medium. A control sample of non-tabletted freeze-dried S. boulardii (200 mg) (batch 6) was tested in the same conditions of acidic exposure for 120 min. The viable yeasts were enumerated using the plate culture method described above. Experiments were carried out in triplicate. Results were expressed in log cfu/g of yeast.
Formulation of Microspheres. Preparation One and eight tenths of sodium alginate were dissolved in 70, 78, 85 or 94 ml of sterile water. The aqueous suspension of S. boulardii (batch 2) was added in the sodium alginate solution in the amount between 8 and 40 g (Formulations A, B, C, D, Table 1 ). The suspension mixture introduced into a 20 ml syringe was extruded through a 26 G needle using a dynamometer DY20B (Adamel Lhomargy, Ivry, France) at a constant speed of 1 mm/min. The nitrogen gas flow (60 mBar), was kept 1 cm away from the suspension flow, in order to generate small drops which formed microspheres in 0.1 M CaCl 2 solution. The microspheres were left to harden for at least 30 min in 0.1 M CaCl 2 solution under continuous magnetic stirring. The microspheres were collected, rinsed twice with sterile water and dried in an oven for 3 d at ϩ25°C.
Characterisation Preparation yield (Y) was calculated as follows:
Where Wt is the final weight of the dried microspheres and W0 is the initial weight of dried material contained in the volume of suspension processed. Results were expressed as percentages.
The equivalent diameter (ED expressed in mm) and the shape factor (SF) were assessed using optical microscopy (Labophot-2A, Nikon, Tokyo, Japan) and Visiolab 1000 version V2-50 software (Biocom, Les Ulis, France) according to the following equations:
February 2008 267 Where A is the area and P is the perimeter of the microspheres. Data were collected from 10 microspheres in each sample. The viable yeast content in the microspheres was determined by a disintegration method in pH 6.8 phosphate buffer solution at room temperature. Samples of the resultant suspension were removed and the viable yeasts were enumerated using the plate culture method described above. Entrapment efficiency was calculated as the percentage of viable yeast within the microspheres in relation to the initial amount employed. Results were based on triplicate determinations.
In order to evaluate the release of viable yeast from microspheres, the latter (200 mg in dry extract) were placed in 10 ml of 0.1 N HCl for 2 h under magnetic stirring at room temperature. After incubation, the microspheres were removed, filtered and rinsed twice with sterile water. The washed microspheres were then placed in 10 ml of pH 6.8 phosphate buffer for 2 h in the same conditions of stirring and temperature. Samples were collected at 15, 30, 60 and 120 min in each medium. A control sample of non-encapsulated S. boulardii in aqueous suspension (200 mg in dry extract) (batch 3) was tested in the same conditions of acidic exposure for 120 min. The viable yeasts were enumerated using the plate culture method described above. Experiments were carried out in triplicate. Results were expressed in cfu/g of yeast.
Statistical Analysis Results are presented as meanϮ S.D. Statistical analysis was performed using one way ANOVA followed by Student's test. Differences between means were considered significant at pϽ0.05.
RESULTS

Morphological and Ultrastructural Analysis of S.
boulardii Under scanning electron microscopy, the yeast in aqueous suspension was characterized by an ovoid or spherical shape. The wall was smooth and some bud scars were visible, testifying to the asexual reproduction of the yeast (Fig. 1A) . The freeze-dried yeast presented a similar morphology (Fig. 1B) .
Under transmission electron microscopy, the cytoplasm was dense in 98% of the yeasts in aqueous suspension and light in 2% of the cells (Fig. 1C) and it contained small vacuoles (Fig. 1E) . Freeze-drying process led to a clarifying of the cells and the ratio of dense/light cytoplasm was 80%/20% of the freeze-dried yeasts (Fig. 1D) . The light aspect of the cytoplasm was associated to an increase in number and size of vacuoles and appearance in the cytoplasm of lighter zones with heterogeneous content (Fig. 1F) .
Influence of Handling/Storage Conditions on the Survival of S. boulardii. Yeast in Aqueous Suspension The initial viability of S. boulardii in aqueous suspension (batch1) was 6.4Ϯ2.9ϫ10
10 cfu/g (10.8Ϯ0.3 log cfu/g) at day 0. The viability of the yeast in aqueous suspension was maximum at time 0 and no significant change in the viability could be observed for one year of storage at ϩ5°C in aerobic and anaerobic conditions and Ϫ20°C in aerobic condition (data not shown). A loss of viability was observed after one year at Ϫ20°C in anaerobic condition (2.3Ϯ1.6ϫ10
10 cfu/g, pϭ0.04 vs. day 0). The higher the temperature, the more important the loss of viability of the yeast in aqueous suspension: at ϩ25°C in aerobic conditions, the loss of viability was significant from day 90 (1.0Ϯ1.1ϫ10
6 cfu/g, pϭ0.02 vs. day 0) and reached 7 log after one year (residual viability: 3.1Ϯ2.3ϫ10 3 cfu/g, pϽ0.05 vs. day 0). The same pattern was observed in anaerobic conditions. At ϩ40°C and ϩ60°C (Fig. 2 ) the viability dropped quickly in 4 d and 1 d, respectively (pϽ0.05 vs. day 0). The mortality was almost total (detection limit of 10 2 cfu/g) in 14 and 4 d, at ϩ40°C and ϩ60°C, respectively.
Under scanning electron microscopy, S. boulardii exposed for one day at ϩ60°C in aerobic condition presented an ovoid or spherical morphology and no alteration of the wall could be observed at the magnification of 5400 (Fig. 3A) . Under transmission electron microscopy, the ratio of dense/ light cytoplasm was 95%/5% (Fig. 3C ) but dense cells were very different from those observed in control samples of the yeast in aqueous suspension: the cytoplasm seemed to be "condensed" and although well preserved, the outline of the wall was more uneven and 5% of the yeasts were slightly distorted.
Freeze-Dried Yeast The initial viability of the freezedried yeast (batch 4) at day 0 was 5.2Ϯ2.2ϫ10
10 cfu/g (10.7Ϯ0.2 log cfu/g). For the control sample stored under ambient conditions, the viability significantly decreased from 6 months (1.03Ϯ0.97ϫ10 10 
Fig. 3. Electron Microscopic Analysis of S. boulardii Stored under Stress Conditions
Scanning electron microscopy (ϫ5400) of the yeast in aqueous suspension after 1 d of storage at ϩ60°C in aerobic condition (A) and the freeze-dried yeast after one day of storage at ϩ60°C with 75% relative humidity (B). Transmission electron microscopy of the yeast in aqueous suspension after 1 d of storage at ϩ60°C in aerobic condition (C ϫ6000) and the freeze-dried yeast after 1 d of storage at ϩ60°C with 75% relative humidity (D ϫ6000) (wd: wall deformation, cc: cytoplasm "condensation").
humidity at ϩ25°C, the viability decreased significantly from day 28 (6.5Ϯ8.7ϫ10 9 cfu/g, pϭ0.04 vs. day 0) and the loss of viability reached 8 log after one year (residual viability 7.7Ϯ7.4ϫ10 2 cfu/g, pϽ0.05 vs. day 0). At ϩ60°C, the significant decrease of the viability started from day 28 under anaerobic conditions and from day 90 under aerobic ones without relative humidity (Fig. 4) . Under aerobic conditions with 75% relative humidity, the mortality of the yeast was almost total with 5 log of reduction within 1 d. The residual viable yeast number was 5.7Ϯ1.3 log cfu/g compared to 10.7Ϯ 0.2 log cfu/g at day 0 (pϭ0.03). In scanning electron microscopy, under the same conditions, the morphology of the freeze-dried yeast showed deformations and alterations of the wall (Fig. 3B) . Under transmission electron microscopy, the cytoplasm was dense in 40% of the freeze-dried yeast and light in 60% of the cells (Fig. 3D) . No image of cytoplasm "condensation" could be observed among dense yeasts. Wall deformations were present in 5% of the cells.
Tablet Characteristics. Uniformity of Mass, Resistance to Crushing, Friability and Disintegration Time Two batches of tablets weighing 600Ϯ3 mg and 599Ϯ1 mg were prepared with a hardness of 35Ϯ2 N and 79Ϯ6 N, respectively. Tablets with the lowest hardness were not conform to the European Pharmacopoeia (5th edition) requirements concerning their friability (Ͼ1%) whereas tablets with the highest hardness were conformed to it, with a loss of mass of 0.55%. The disintegration time was above 15 min for both formulations, as expected for matrix tablets.
Influence of Tabletting on Yeast Viability
The initial viability of the freeze-dried yeast (batch 5) was 2.3Ϯ0.3ϫ 10 10 cfu/g of yeast. After compression, the viable yeast content within tablets was 1.5Ϯ0.4ϫ10 10 (64%) and 4.6Ϯ0.3ϫ 10 9 cfu/g (20%) of yeast tabletted at the lowest and the highest hardness, respectively. The compression significantly decreased the viability of the freeze-dried yeast in both tablet batches and the compression force significantly altered the viability of the yeast (pϽ0.05). (Fig. 5) The viability of the control sample of non-tabletted freeze-dried (FD) yeast (batch 6) in 0.1 N HCl decreased significantly from 2.6Ϯ0.2ϫ10 10 to 7.9Ϯ2.5ϫ10 9 cfu/g of yeast in the first 5 min (pϽ0.05 vs. time 0) and was less than 1% of viable yeast after 120 min (4.0Ϯ3.6ϫ10 5 cfu/g, pϽ0.05 vs. time 0). The initial release of viable yeasts from tablets (79Ϯ6 N) in 0.1 N HCl was fast and reached a maximum value of 1.54Ϯ0.28ϫ10
Viability of the Freeze-Dried Yeast or That Released from Tablets in Vitro
7 cfu/g of yeast at 15 min. This initial release was followed by a significant decrease in probiotic viability to the lowest values of 2.63Ϯ0.83ϫ10 6 cfu/g of yeast at 60 min. No disintegration occured in HCl, the release of viable yeasts was partial (Ͻ1%) in this medium and achieved a relative plateau up to 120 min. In pH 6.8 phosphate buffer solution, disintegration of the tablet occured after 60 min and the progressive release of viable yeast led to a total of 1.41Ϯ0.12ϫ10 9 cfu/g at 240 min, which corresponds to a 30% loss of viability compared to the initial content of viable yeasts in the matrix tablets.
Microsphere Characteristics. Size, Shape, Entrapment Efficiency and Preparation Yield (Table 2 ) Microspheres were monodisperse with a spherical shape in all batches. The amount of yeast in aqueous suspension significantly influenced the equivalent diameter and the shape factor. Formulation D, which allowed a small diameter and a satisfactory shape factor (close to one) along with the highest incorporation of probiotic, was further studied.
In this formulation, the number of viable yeasts recovered in pH 6.8 phosphate buffer was 4.00Ϯ0.99ϫ10
10 cfu/g of yeast. Compared to the initial number of viable S. boulardii in the aqueous suspension (batch 2) used to prepare the mi- The initial release of viable yeasts from microspheres in 0.1 N HCl was fast and reached a maximum at 60 min. The release of viable yeasts was partial (Ͻ10%) in this medium and achieved a relative plateau up to 120 min. In pH 6.8 phosphate buffer solution, the microspheres were totally disintegrated after 5 min leading to a significant total release of 3.46Ϯ2.38ϫ10
10 cfu/g of viable yeast. The final number of viable yeasts obtained after 240 min was not different from the initial content of viable yeasts in the microspheres.
DISCUSSION
In the present study, we assessed the survival conditions of S. boulardii in order to formulate pharmaceutical dosage forms aiming to preserve the viability of the yeast. Although a number of studies have been carried out to determine the viability conditions of the Saccharomyces cerevisiae strains as an alimentary product, [15] [16] [17] [18] very few data are available concerning S. boulardii. 14) It is important to note that despite being a subtype of S. cerevisiae yeast species known as S. cerevisiae Hansen CBS 5926, S. boulardii is clearly distinguishable from S. cerevisiae and possesses strain-specific beneficial properties. 19) Because most pharmaceutical industrial processes may induce an increase of the temperature of the handled material and may expose it to relative humidity, the viability of the yeast was studied at different temperatures in the presence or absence of relative humidity. These temperatures and moisture conditions were selected according to the guidelines of the International Conference on Harmonisation of technical requirements for the registration of pharmaceuticals for human use. 20) We tested the freeze-dried form of S. boulardii which is the commercially available one and the aqueous suspension of the yeast from which it was obtained by freezedrying, in order to determine whether both forms could be equally handled as raw materials. It is noteworthy that before any treatment, the initial viability of freeze-dried yeast is 20 to 30% lower than that of the aqueous suspension due to the lyophilisation process. As a consequence, the freeze-dried yeast is also less sensitive to temperature elevation. The viability of freeze-dried S. boulardii can be maintained by storage under aerobic or anaerobic conditions at ϩ25°C without relative humidity for at least one year. These data are in accordance with the actual storage conditions of the commercially available freeze-dried forms whose shelf-like lasts at least 24 months. As expected for a freeze-dried material, moisture is a crucial parameter which influences viability. Indeed, at the same temperature of ϩ25°C, 75% of relative humidity leads to an important loss of viability of the freezedried form after one year of storage. Increasing the temperature of storage to ϩ60°C accelerates the loss of viability and the combination with 75% relative humidity is fatal for the yeast whose mortality is almost total within one day. The deleterious effect of temperature on the viability of the yeast is even more pronounced when it is in aqueous suspension. In aqueous suspension the increased sensitivity of the yeast to temperature rise is clearly underlined by transmission electron microscopic analysis which shows morphological alterations typical of cell death. 21, 22) The mortality occurring within 14 and 4 d respectively at ϩ40°C and ϩ60°C could be attributed to the heat shock that happens when samples are placed directly in the oven set at the tested temperatures rather than to nutrient starvation. Indeed, Gervais and Martinez de Maranon 23) as well as Beney et al., 24) when studying suspensions of S. cerevisiae, showed that a fast temperature increase in the temperature range between ϩ40°C and ϩ50°C induces high yeast mortality whereas an increase at 0.42°C per minute avoids the heat shock and thus maintains high cell viability. On the other hand, the viability of the yeast in aqueous suspension is unaltered when stored at ϩ5 and Ϫ20°C. It can therefore be concluded from the first part of this study that the storage conditions that preserve the viability of S. boulardii are temperatures equal to or lower than ϩ25°C without relative humidity for the freeze-dried yeast and equal to or lower than ϩ5°C for the yeast in aqueous suspension for at least one year. Viability of both forms is also maintained at room temperature for several days allowing for dosage form fabrication.
The poor survival of both forms of S. boulardii in acidic condition warrants the development of formulations able to protect the probiotic from degradation. In order to preserve the 100% viability of the yeast in aqueous suspension, alginate microspheres were prepared by using an extrusion method followed by a drying at mild temperature. Microencapsulation by the extrusion process is a method of choice to protect probiotics from degradation during the gastrointestinal transit [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and sodium alginate at an optimised concentration of 1.8% (w/v), 36) is the most used polymer. It presents the benefits of being non-toxic, biodegradable and biocompatible. 37) In our study, the extrusion method with sodium alginate enables to obtain monodisperse microspheres that are highly loaded with viable yeasts (entrapment efficiencyϭ 52%) and present a spherical shape. The non disintegration of these microspheres in HCl pH 1.1 allows minimising the loss of viability of the probiotic in acidic condition while their fast disintegration in phosphate buffer at pH 6.8 leads to a total release of viable yeasts. The partial release followed by a plateau up to 120 min in HCl suggests that, following the initial release which probably corresponds to the yeasts entrapped onto the surface of the microspheres and is concomittant with a significant loss of viability, an apparent equilibrium is achieved with the amount of S. boulardii released equalling the decrease in probiotic viability.
As for the freeze-dried yeast, matrix tablets were formulated by direct compression with hydroxypropylmethylcellulose which is the most used hydrophilic polymer for the fabrication of controlled drug delivery systems. 38) In our study, the low compression force tested-which preserved 64% of viability-does not allow obtaining matrix tablets comform to the European Pharmacopoeia friability requirements. To achieve this goal, it is necessary to apply a higher compression force that leads to a 80% loss of viability of the probiotic. Taking into account that the initial viability of the freeze-dried yeast is 20 to 30% lower than that of the yeast in aqueous suspension, direct compression of the lyophilised probiotic seems to be less effective than the microencapsulation method with the aqueous suspension in terms of loading of the dosage form with viable S. boulardii. However, this phenomenon is balanced by a better resistance, in acidic conditions, of matrix tablets than that of microspheres resulting in a lower number of viable yeasts released. This could be partly explained by the swelling of hydroxypropylmethylcellulose which forms a gelling barrier limiting the release of viable yeasts (2 log units lower after incubation for 2 h in acidic medium compared to microspheres). An additionnal explanation could be the size of the matrix tablet which is about 40-fold larger than that of microspheres. Chandramouli et al., 36) have shown that the viability of encapsulated bacteria in simulated gastric conditions increased with larger capsule size (200-1000 mm). Finally, although both processes of fabrication are easy to implement, microspheres present more advantages than matrix tablets: no expensive freezedrying process, higher entrapment efficiency, faster release of viable yeast at pH 6.8 and easier adaptation of the dose.
CONCLUSION
Based on the survival conditions of S. boulardii whose viability is maintained at room temperature for several days, protective formulations can be prepared by direct compression of the freeze-dried yeast as well as microencapsulation of the probiotic in aqueous suspension. Although both formulations are efficient in protecting S. boulardii from degradation in acidic condition, microspheres provide a higher entrapment efficiency and a faster release of the viable probiotic in intestinal condition than matrix tablets.
